Company profile
HexemBio
Extending Your Healthspan I Breakthrough Stem Cell Rejuvenation Therapy
- Industry
- Biotechnology Research
- Employees
- 13
- Headquarters
- New York, NY
- Founded
- 2024
- LinkedIn followers
- 1,601
- Office locations
- 1
HexemBio company summary
HexemBio is a company in the Biotechnology Research industry, headquartered in New York, NY, founded in 2024. On LinkedIn the company has around 13 employees and 1,601 followers.
What technology does HexemBio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About HexemBio
HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patient's own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley. To learn more, visit hexemb.io.
Where is HexemBio located?
HexemBio lists 1 location.
Compare companies similar to HexemBio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
HexemBio hexemb.io | Biotechnology Research | 13 | 2024 | New York, NY |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about HexemBio
What does HexemBio do?
HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patient's own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley. To learn more, visit hexemb.io.
How many employees does HexemBio have?
HexemBio has around 13 employees on LinkedIn.
Where is HexemBio headquartered?
HexemBio is headquartered in New York, NY.
When was HexemBio founded?
HexemBio was founded in 2024.
Build a lead list from companies like HexemBio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.